CASI Pharmaceuticals Inc (CASI) PT Set at $4.00 by Maxim Group
CASI Pharmaceuticals Inc (NASDAQ:CASI) received a $4.00 price objective from analysts at Maxim Group in a note issued to investors on Monday. The firm currently has a a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 142.90% from the company’s previous close.
Shares of CASI Pharmaceuticals (NASDAQ:CASI) opened at 1.6468 on Monday. CASI Pharmaceuticals has a 12 month low of $0.58 and a 12 month high of $1.70. The stock’s 50 day moving average is $1.35 and its 200 day moving average is $1.22. The firm’s market capitalization is $81.45 million.
CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.05. Equities research analysts forecast that CASI Pharmaceuticals will post ($0.28) earnings per share for the current fiscal year.
In other news, Director Wei-Wu He purchased 1,871,605 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were purchased at an average cost of $1.19 per share, with a total value of $2,227,209.95. Following the completion of the transaction, the director now owns 24,698 shares of the company’s stock, valued at approximately $29,390.62. The transaction was disclosed in a filing with the SEC, which is available through this link.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Stock Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.